

## Izalontamab

Cat. No.:	HY-P99676
CAS No.:	2559704-24-2
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer <sup>[1]</sup> .								
<b>In Vivo</b>	<p>Izalontamab (5-46 mg/kg; i.v., every 7 days once, 4 doses in total) shows different anti-tumor efficacy in different types of tumors<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Female NOD/SCID mouse with SW48, FaDu and KYSE-150 xenografts<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150)</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150); every 7 days once, 4 doses in total</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently inhibited the growth of FaDu and KYSE-150 tumors at the dose of 10 mg/kg. Inhibited 63.6% SW48 tumor growth at the dose of 46 mg/kg.</td> </tr> </table>	Animal Model:	Female NOD/SCID mouse with SW48, FaDu and KYSE-150 xenografts <sup>[1]</sup>	Dosage:	10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150)	Administration:	Intravenous injection; 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150); every 7 days once, 4 doses in total	Result:	Dose-dependently inhibited the growth of FaDu and KYSE-150 tumors at the dose of 10 mg/kg. Inhibited 63.6% SW48 tumor growth at the dose of 46 mg/kg.
Animal Model:	Female NOD/SCID mouse with SW48, FaDu and KYSE-150 xenografts <sup>[1]</sup>								
Dosage:	10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150)								
Administration:	Intravenous injection; 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150); every 7 days once, 4 doses in total								
Result:	Dose-dependently inhibited the growth of FaDu and KYSE-150 tumors at the dose of 10 mg/kg. Inhibited 63.6% SW48 tumor growth at the dose of 46 mg/kg.								

### REFERENCES

[1]. Xue J, et al. Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. J Pharm Sci. 2020 Oct;109(10):3172-3180.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA